Research workbench
Complex of mbp-C and bivalent man-terminated glycopeptide
Analyse Complex of mbp-C and bivalent man-terminated glycopeptide in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.
- PDB
- 1KZE
- Type
- protein
- Length
- 223 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Mannose-binding protein C
- UniProt
- P08661
- Ligands
- MAN, CA, CL
- Pockets
- 1 · best druggability 0.30
Structure
x-ray diffraction · 2 distinct chains · 18% helix, 31% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| 1 | Mannose-binding protein C | protein | 111 | 18% helix, 29% strand | P08661 |
| 2 | Mannose-binding protein C | protein | 112 | 18% helix, 34% strand | P08661 |
Ligands and binding sites
- MAN · alpha-D-mannopyranose · sugar · 2 copies · chains 1, 2
- CA · Calcium ion · metal · 4 copies · chains 1, 2
- CL · Chloride ion · ion · chains 1
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
1 pocket found on a 1 Å grid, 0 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 75 | 0.30 | 0.73 | 12 | empty |
Interfaces
1 interface between chains.
- 1–2 · 704 Ų buried · 9 hydrogen bonds · protein-protein
Modifications
Observed in the structure: 4 disulfide (disulfide).
Compared structures
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P08661
- Elsewhere: RCSB PDB 1KZE · PDBe 1KZE · UniProt P08661
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.